



Consolidated Statements of Operations
(Amounts in thousands, except per share amounts)
(Unaudited)

	June 28, 2024	September 27, 2024	December 31, 2024	March 28, 2025	June 27, 2025	September 26, 2025	December 31, 2025	April 3, 2026
Revenue	\$ 235,864	\$ 244,405	\$ 238,060	\$ 233,366	\$ 241,049	\$ 247,836	\$ 258,349	\$ 257,707
Cost of revenue	132,175	135,190	129,835	129,012	134,303	136,915	145,086	144,129
Gross profit	103,689	109,215	108,225	104,354	106,746	110,921	113,263	113,578
Operating expenses:								
Research and development and engineering	23,731	23,253	25,285	23,238	25,289	24,090	22,867	23,251
Selling, general and administrative	44,793	44,319	43,301	45,596	47,103	51,378	51,582	54,409
Amortization of purchased intangible assets	6,907	6,589	6,548	5,554	6,871	6,928	8,124	5,774
Restructuring, acquisition, and related costs	2,543	2,499	6,384	(2,455)	12,572	6,677	5,858	2,605
Total operating expenses	77,974	76,660	81,518	71,933	91,835	89,073	88,431	86,039
Operating income	25,715	32,555	26,707	32,421	14,911	21,848	24,832	27,539
Interest income (expense), net	(8,266)	(8,079)	(6,890)	(5,644)	(5,815)	(6,014)	(3,999)	(1,843)
Foreign exchange transaction gains (losses), net	(264)	(202)	1,200	(368)	(2,744)	14	908	731
Other income (expense), net	(55)	(49)	(222)	9	(563)	(90)	(64)	(73)
Income before income taxes	17,130	24,225	20,795	26,418	5,789	15,758	21,677	26,354
Income tax provision (benefit)	3,375	5,033	4,331	5,210	1,292	5,105	4,206	5,255
Net income	\$ 13,755	\$ 19,192	\$ 16,464	\$ 21,208	\$ 4,497	\$ 10,653	\$ 17,471	\$ 21,099
Earnings per common share:								
Basic	\$ 0.38	\$ 0.53	\$ 0.46	\$ 0.59	\$ 0.12	\$ 0.30	\$ 0.46	\$ 0.52
Diluted	\$ 0.38	\$ 0.53	\$ 0.46	\$ 0.59	\$ 0.12	\$ 0.30	\$ 0.45	\$ 0.51
Weighted average common shares outstanding—basic	35,946	35,959	35,980	36,024	36,022	35,967	38,237	40,425
Weighted average common shares outstanding—diluted	36,092	36,129	36,148	36,130	36,076	36,040	38,681	41,158
Adjusted EBITDA (Non-GAAP):								
Net Income (GAAP)	\$ 13,755	\$ 19,192	\$ 16,464	\$ 21,208	\$ 4,497	\$ 10,653	\$ 17,471	\$ 21,099
Interest (income) expense, net	8,266	8,079	6,890	5,644	5,815	6,014	3,999	1,843
Income tax provision	3,375	5,033	4,331	5,210	1,292	5,105	4,206	5,255
Depreciation and amortization	14,116	14,155	14,363	13,563	15,581	15,711	17,077	14,160
Share-based compensation	6,231	6,364	4,635	7,100	7,498	6,698	8,242	9,796
Restructuring, acquisition and related costs	2,548	2,491	6,376	(3,106)	12,091	6,156	5,302	2,098
Inventory related charges associated with a product line closure	2,493	-	-	-	65	-	-	-
Officer transition costs	-	1,411	-	-	-	1,137	-	-
Planning and design phase of the financial and operation system implementation	-	-	-	-	1,693	3,519	2,392	2,658
Costs incurred for insurance recovery claim	-	-	-	-	324	3,042	2,854	-
Operational transformation costs	-	-	-	-	-	-	-	556
EU medical device regulation charges	-	-	-	-	-	-	-	269
Other, net	319	251	(978)	359	3,307	76	(844)	(658)
Adjusted EBITDA (Non-GAAP)	\$ 51,103	\$ 56,976	\$ 52,081	\$ 49,978	\$ 52,163	\$ 58,111	\$ 60,699	\$ 57,076